Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Galera Therapeutics, Inc. (GRTX : NSDQ)
 
 • Company Description   
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which is designed to rapidly convert superoxide to hydrogen peroxide. Galera Therapeutics, Inc. is headquartered in Malvern, PA.

Number of Employees: 30

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.67 Daily Weekly Monthly
20 Day Moving Average: 211,813 shares
Shares Outstanding: 26.82 (millions)
Market Capitalization: $44.79 (millions)
Beta: 2.40
52 Week High: $10.79
52 Week Low: $1.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.36% -3.55%
12 Week -25.11% -17.68%
Year To Date -63.62% -52.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2 WEST LIBERTY BOULEVARD SUITE 100
-
MALVERN,PA 19355
USA
ph: 610-725-1500
fax: -
help@astfinancial.com http://www.galeratx.com
 
 • General Corporate Information   
Officers
J. Mel Sorensen - Chief Executive Officer; President and Director
Michael Powell - Chairman
Christopher Degnan - Chief Financial Officer
Lawrence Alleva - Director
Emmett Cunningham - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 36338D108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 26.82
Most Recent Split Date: (:1)
Beta: 2.40
Market Capitalization: $44.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.36 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 45.68% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 22.67%
vs. Previous Quarter: 9.38%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -83.88
12/31/21 - -87.58
09/30/21 - -90.93
Current Ratio
03/31/22 - 5.97
12/31/21 - 5.98
09/30/21 - 5.89
Quick Ratio
03/31/22 - -
12/31/21 - 5.98
09/30/21 - 5.89
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -2.63
12/31/21 - -2.19
09/30/21 - -1.64
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©